Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma

Moran Amit, MD, PhD, a head and neck surgical oncologist at UT MD Anderson came to psychedelic research through an unexpected path. His original work focused on how tumors hijack the nervous system, which led him to investigate tryptamines—the drug family that includes psilocybin—as potential tools to reverse that process. This research intersected with a problem he saw constantly in his clinical practice: head and neck cancer carries one of the highest suicide rates among cancer types, partly because treatment can leave visible, unconcealable physical changes that isolate patients even after they're medically cured.

Amit's team is now running 2 clinical trials using psilocybin-assisted psychotherapy. The first targets patients undergoing active treatment with curative intent, a population largely overlooked by prior psychedelic research, which has focused mainly on terminally ill patients. The second serves cancer survivors who remain burdened by trauma from diagnosis and treatment, a group Amit compares to veterans struggling to readjust after returning home.

Both trials follow a structured protocol built around two dosing days in a deliberately nonclinical setting, with 2 therapists monitoring patients throughout. Preparation sessions establish the right mindset beforehand, and integration sessions follow each dosing day to help patients process the experience. Amit emphasizes that careful "set and setting" distinguishes this clinical protocol from psychedelics' recreational associations.

Key open questions include safety when combining psilocybin with radiation or chemotherapy, and logistical challenges like dosing patients who cannot speak or swallow. While full data isn't yet available, Amit reports encouraging safety signals and transformative feedback across dozens of patients treated so far. Looking ahead, his team is also planning a trial examining whether psilocybin can mitigate physical treatment toxicities, particularly neurotoxicity, extending the research beyond mental health outcomes into somatic applications.

Read the full interview with Dr Amit here.